- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 5074
Name: tumour necrosis factor shed form
Abbreviated name: TNF shed form
View more information in the IUPHAR Pharmacology Education Project: tumour necrosis factor alpha
|Compound class||Endogenous peptide in human, mouse or rat|
|Ligand families/groups||Tumor necrosis factor superfamily ligands|
|cachectin | necrosin | TNF alpha soluble form | tumor necrosis factor soluble form|
|TNFα is a pro-inflammatory, acute phase cytokine involved in systemic inflammation.
The TNF precursor is expressed as a membrane-bound ligand, which is cleaved by TACE/ADAM17 to form this shed (or 'soluble') bioactive cytokine containing just the extracellular domain, and that circulates predominantly as a homotrimer. Recombinant TNF is used as an immunostimulant under the INN tasonermin.
Circulating active TNF-α is the principal molecular target of the anti-TNF therapeutics infliximab and adalimumab. A smaller and longer acting anti-TNF biologic called V565 is in early stage clinical development . V565 is a heavy chain only variable domain anti-TNF construct generated in Ilama and modified to further enhance resistance to protease-mediated degradation. It binds shed TNF-α with similar affinity to infliximab and adalimumab, and also inhibits biological responses mediated by membrane-bound TNF-α . If this design strategy proves successful, V565 will be the first orally active anti-TNF therapy. V565 is being evaluated for potential to treat Crohn's disease (see Phase 2 study NCT02976129).
|DrugBank Target||P01375 (Hs)|
|Ensembl Gene||ENSG00000204490 (Hs)|
|GtoPdb PubChem SID||178101767|
|Human Protein Atlas||ENSG00000204490 (Hs)|